INTRODUCTION
Our understanding of the molecular biology of bovine virus diarrhoea virus (BVDV) is in its infancy as compared to other viruses such as vesicular stomatitis, influenza and the retroviruses. There are several reasons for the rather slow progress in the area of the molecular biology of pestiviruses:
1. This group of viruses has no identifiable members which cause human disease, and as a consequence, monies for research on these viruses have not been plentiful.
2. These viruses do not produce a bountiful yield of viral products in the infected cell.
3. The pestiviruses do not lend themselves to the traditional methods of purification and analysis. As will be discussed later, there are no conclusive data on the virion structure of the pestiviruses. 4 . The animal models for pestiviruses are not conducive to the large-scale studies which would be necessary to relate genetic manipulations of the virus and pathogenesis. 5 . The failure to recognise the widespread contamination with BVDV of cell lines and serum supplements certainly hindered the quality of early research on pestiviruses.
Additionally, the problem of BVDV contamination of biological products (e.g. vaccines) and the existence of animals persistently infected with BVDV casts a shadow of doubt over many clinical studies, unrelated to this virus, involving cattle, sheep and swine. However, with the evolving techniques of molecular biology, considerable progress has recently been made on BVDV. The areas of progress will be discussed with an eye towards the significance of these findings for the understanding of the pathogenesis of BVDV and for the diagnosis and prevention of clinical disease.
VIRION PROTEINS
As stated previously, the identity of the proteins which comprise the virion of BVDV is largely unknown. Interest in these proteins is not driven by just intellectual curiosity; the successful construction of subunit vaccines depends upon an accurate catalogue of these virion proteins. The relatively low yields of BVDV have made it difficult to obtain the necessary amounts of radiolabelled virus needed for a vigorous purification procedure. The nature of the virus and its morphogenesis may make an absolute determination of virion structural components, based on biochemical techniques alone, nearly impossible. A combination of these techniques and structurefunctions studies of the individual proteins encoded by the virus may define the ultimate structure of the virion. Table I lists the results of several conventional efforts that attempted to identify the virion proteins of BVDV. For comparison, the results of an attempt to define the hog cholera virion (16) are included. In discussing viral polypeptides, I will use the nomenclature as suggested by Collett, Moennig and Horzinek (4). In some instances, this may require some "best guess" matching of the proposed designations with the reported molecular weights. All of the reports listed in Table I appear to have identified a glycoprotein of about 55K (gp53) in the enriched or purified preparations. As will be discussed below, a similar glycoprotein is found in the BVDV infected cell. Supporting evidence that gp53 is a major virion protein comes from two different areas of research. There are several reports describing the identification of monoclonal antibodies (MAB's) specific for gp53 which have virus neutralising activity (2, 14, 17) . By analysing the reactivity patterns of 70 BVDV isolates, Corapi and Dubovi identified 10 different groups of neutralising MAB's specific for gp53 (7) . One neutralising MAB reacted only with the Singer strain of BVDV which was used to produce the MAB's while one MAB reacted with 98% of the isolates tested. The existence of multiple neutralising sites on gp53 has also been noted in a recent review of pestivirus research (4). While not conclusive, the existence of neutralising MAB's specific to gp53 is highly supportive of a virion location for gp53.
Additional support for the virion location of gp53 can be found in the efforts to produce a vaccinia-vectored BVDV vaccine. A cDNA clone of a segment of BVDV was inserted into a cDNA clone of the equine influenza HA gene. This construct was used to select recombinant vaccinia viruses (VAC-BVDV) carrying the hybrid sequence. Mice and cattle infected with the recombinant virus developed neutralising antibodies to BVDV (15; Dubovi and Dale, unpublished observation). Sera from the mice were used to immunoprecipitate radiolabelled extracts from BVDV-infected cells. The only BVDV-specific polypeptide identified by this procedure was gp53 (15) . In addition, MAB's specific for gp53 recognised the hybrid protein in VAC-BVDVinfected cells. Polypeptides which evoke the production of virus neutralising antibodies are found in the virus particle. There is no reason to believe that this is not the case for gp53. Regardless of its location, the MAB and recombinant vaccinia studies have identified a key antigen of BVDV which should be included in any subunit vaccine.
With regard to the other virion proteins, their identity is much less convincing than gp53. With the data for hog cholera virus included, two of the five reports listed in Table I identified a protein of 44-47K which is also glycosylated (gp48). As will be discussed later, a similar entity exists in the BVDV infected cell. Unlike gp53, there are no published reports identifying MAB's to gp48 which are neutralising. Corapi and Dubovi (7) have identified two MAB's to gp48 but these do not show any virus neutralising activity even with the addition of anti-mouse immunoglobulin and com plement. The limited selection of MAB's to gp48 does not permit speculation as to its possible location in the virion or its contribution to the induction of BVDV immunity.
The identity of a nucleocapsid protein of BVDV is also unknown. Most speculation has centered on the 34-38K nonglycosylated protein found in some virus preparations. However, the recent determination of the genomic organisation of BVDV suggests the possibility that a 20K (p20) protein identified in infected cells may actually be the nucleocapsid protein (4, 5) . The presence of other viral proteins in the virion such as gp25 cannot be determined at this time although two reports indicate the presence of a protein of this size in the virion preparations.
BVDV-INDUCED POLYPEPTIDES IN INFECTED CELLS
The analysis of the virus-induced polypeptides in the BVDV infected cell has been hampered by the relatively small amount of virus antigen found in infected cells and by the fact the BVDV is very inefficient in inhibiting host cell mRNA and protein synthesis. While these are major problems with the cytopathic strains of BVDV, they are nearly insurmountable problems with the less replication-competent non-cytopathic strains. In order to circumvent these problems, most studies on the BVDV specific polypeptides in infected cells have utilised the technique of immunoprecipitation in which sera containing antibodies to BVDV proteins are used to select radiolabelled polypeptides from an infected cell extract. The quality of the analysis is directly dependent on the quality of the sera used for the selection process. Another potential problem with this type of analysis is the common finding that nonviral proteins can become associated with viral proteins and be co-precipitated. The limitations of the immunoprecipitation technique must be kept in mind when analysing these types of data.
Given the potential problems in analysing BVDV-infected cell extracts for viral induced polypeptides, there is remarkable agreement among the various reports dealing with this question (Table II) . The polypeptides which are most consistently found in the infected cell are pl20, p80, gp62, gp53, gp48, p37 and gp25. While the general patterns for most BVDV isolates are similar, considerable heterogeneity exists in the molecular weights of the individual polypeptides (13, 17, 20) . This is particularly evident for the glycoprotein designated gp53 (13, 17, 20) . Even with the use of MAB's specific for gp53, the Polyacrylamide gel electrophoretic analysis of the Singer strain consistently yields three distinct bands while NADL shows two bands and C24V one band in the molecular weight range of 55-58K (Corapi and Dubovi, unpublished observation). The cause for this high degree of heterogeneity must certainly lie in different levels of glycosylation of the protein core (5, 11). As indicated earlier, gp53 is consistently found in virion preparations and is a major antigen of BVDV which stimulates the bovine immune response. 125  120  120  115  118  pl25  gpll6  gpll8  80  87  80  80  80  p80  75  gp75  gp62  gp69  gp65  gp61  gp65  gp62  58  54  gp53  gp57  gp55  gp56  gp56  gp53  48  gp49  gp47  gp46  gp48  gp48  37  38  37  37  p38  33  32  gp25  gp23  gp26  25  gp25  gp25  p20  19 Three other glycoproteins are consistently found in infected cells, gp62, gp48 and gp25. As will be discussed below, data exist which indicate that gp62 is a precursor of gp48 and gp25 (5) . Evidence supporting the relatedness of gp62 and gp48 was found using a MAB specific for gp48 in immunoprecipitation reactions. In all instances where gp48 was immunoprecipitated, gp62 could also be detected (7, 14) . While gp25 is somewhat difficult to detect in many infected cell preparations, it has been recognised in most studies with infected cell extracts (Table II) .
TABLE II

BVDV-specific polypeptides in infected cellsa
Two other glycoproteins have been identified in infected cell extracts. A major glycoprotein designated gp75 by Donis and Dubovi (11) appears to have been gp62 migrating somewhat anomalously. This was confirmed by examining samples immunoprecipitated with the MAB specific for gp48. In the earlier analyses, a glycoprotein of 75K was also identified, but the 65K protein was absent (14) . Later studies show the 65K protein but not the 75K (7). The reason for this apparent shift in the migration of this protein is not clear. The other glycoprotein identified by Donis and Dubovi (11) , gpll8, appears to be an unprocessed precursor of the three glycoproteins encoded by the 5' end of the BVDV genome (5). While it was initially suggested that pl25 may contain carbohydrate residues, evidence was available to contradict this notion. As will be discussed below, cells infected with cytopathic strains of BVDV have significantly less pl25 than cells infected with non-cytopathic strains. However, gpll8 was detected only in extracts from cells infected with the cytopathic strains (13; Donis and Dubovi, unpublished observation). Were pl25 to have contained carbohydrate residues, one would have expected the extracts from cells infected with the non-cytopathic strains to contain a greater amount of gpl18 than was found with the cytopathic strains. This was not the case. It appears that p118 (p125) was comigrating with a minor species of a unique gpl18.
As was just alluded to, a major difference is found in extracts from cells infected with cytopathic and non-cytopathic viruses (13, 17, 20) . Extracts from cells infected with non-cytopathic BVDV strains consistently lack the p80 protein and have high amounts of pl25. Purchio et al. (23) had earlier established that pl25 and p80 shared common peptides suggesting that p80 was derived from p125. Several lines of evidence support this finding. Sera from cattle infected with non-cytopathic viruses immunoprecipitate p80 as well as sera from cattle infected with cytopathic viruses (12, 17, 20) . In addition, MAB's specific for p80 also immunoprecipitate pl25 (7). The reason for this observed difference between cytopathic and non-cytopathic viruses with respect to p80 is unknown. Other differences can be found in extracts from cytopathic and non-cytopathic viruses, but these generally relate to the lower amount of virus-specific proteins found in cells infected with the non-cytopathic viruses.
As discussed previously, a p37 protein has been suggested as being the nucleocapsid protein of BVDV. Analyses of infected cell extracts by radioimmunoprecipitation inconsistently detect a p37 protein (1, 12, 17, 20) . Part of the problem lies in the quality of the sera used for the immunoprecipitation. Most field sera do not recognise p37 to a sufficient degree as to be detectable by standard means (12) . Generally, one must use hyperimmune sera to detect p37. With non-cytopathic strains of BVDV, the problem is further complicated by the low level of viral protein expression in the infected cells. Even with hyperimmune sera, the detection of p37 with non-cytopathic strains is unusual.
While the immunoprecipitation data strongly imply a viral origin for the proteins identified, it is necessary to have independent confirmation of these results. The first study to provide this confirmation utilised a combination of metabolic inhibitors to preferentially block host cell protein synthesis (10) . A total of eleven proteins were identified in infected cells which were absent in the uninfected control cells. Proteins which have already been discussed include pi 18 (pl25), p80, p62, p56-58 (gp53), p48, p37 and p25. Proteins not previously discussed include pl65, pl35, p32 and pl9. Protein pl65 was also identified by immunoprecipitation while pl35 has not been identified by this technique. Protein p32 was only detected using 35 S-cysteine as the labelling agent. A protein of similar molecular weight (p33) was detected using immunoprecipitation (20) . Protein pl9 is somewhat unique in that there are no reports identifying this protein using bovine sera and standard immunoprecipitation techniques. It was clearly identified in metabolically inhibited cells using three different radioisotopes (10) . With all of the proteins identified, there was no data obtained which could discriminate virus-encoded proteins from virus-induced proteins.
The most reliable data concerning the number and possible precursor-product relationships among the BVDV proteins have come as a result of the molecular cloning of the NADL strain of BVDV (5, 6) . In these studies, Collett et al. (5) expressed cloned segments of the BVDV genome in bacteria in order to produce defined viral polypeptides for the production of antisera. These peptide specific antisera were used to order the BVDV proteins on the viral genome and to define structural relationships among the proteins expressed in infected cells. Glycoproteins gpll8, gp62, gp53, gp48 and gp25 were identified in BVDV-infected cells extracts. The data suggest that gpl18 is an unprocessed precursor for the mature glycoproteins gp48, gp25 and gp53. Similarly, gp62 is a precursor for gp48 and gp25. Peptide specific antisera also identified pl25 as well as the cleavage products p54 and p80. This finding is consistent with earlier data indicating that pl25 and p80 shared common tryptic peptides (23) . A second large nonglycosylated protein pl33 was found which appears to give rise to a p58 and p75 protein upon further processing. The protein identified at the 5' end of the genome was designated p20. The identification of this protein using the peptide specific antisera was the first confirmation of the existence of a low molecular weight protein in BVDV-infected cells as reported by Donis and Dubovi (10). Collett et al. (5) did not detect a p37 or p32 protein although there are two regions of the genome which could code for proteins of these sizes and for which there were no peptide specific antisera available. While we are nearing a complete catalogue of the BVDV specific proteins, there is a dearth of information on the function(s) of these proteins.
THE BVDV GENOME
The genome of BVDV is composed of RNA of a positive strand polarity. This feature of the virus makes the RNA infectious even in the absence of virion proteins. In infected cells, only a single species of high molecular weight RNA can be detected (22; Dubovi, unpublished observation). The amount and organisation of the genetic material has only recently been elucidated. At present, there are two published reports on the nearly complete nucleotide sequence of BVDV (6, 24) and one report for hog cholera virus (19) . The sequence data for the Osloss strain and for the NADL strain of BVDV indicate a genome of at least 12,492 and 12,573 bases respectively. The hog cholera virus sequence is slightly smaller at 12,284 nucleotides (19) . The data from the Osloss sequence indicated that there were two large open reading frames (ORF's) (24) while the NADL sequence contained only one ORF extending the entire length of the genome (6) . Given that the hog cholera virus data agrees with the NADL sequences as to a single ORF (19) , it seems likely that a cloning error was made in the Osloss sequence as suggested by Collett et al. (4) .
The existence of sequence data from three independent clonings of a pestivirus genome permits some comparisons of sequence homologies. Collett et al. (4) have compared the homology of the NADL and the Osloss strains of BVDV at the amino acid level for the previously identified proteins. With adjustments made for the potential cloning error in Osloss, the homologies ranged from a low of 68% for the p54 protein to a high of 96.3 for the p80 protein. Reactivity patterns for MAB's directed against p80 support a highly conserved amino acid sequence for this protein (7) . The nucleotide sequence for the Singer strain of BVDV spanning a region of p25-p53 has been determined (9) . A three-way comparison of this region shows an amino acid identity of 93.2% between Singer and NADL while the value for Osloss and NADL is 77.8%. A comparison of the sequence and amino acid homology between NADL and the hog cholera virus (Alfort strain) yields about a 66% nucleotide and 85% amino acid homology (19) . These data confirm the close antigenic relationships between BVDV strains and hog cholera virus which have been known for years.
The sequence data reveals several non-homologous regions within the p54 protein coding region. The NADL strain contains an 89 amino acid insertion not found in the Osloss strain. However, the Osloss strain contains a 76 amino acid insertion in an adjacent region of p54 which is unrelated to the sequence in NADL (4). The insertion of 270 nucleotides in NADL has also been noted in the comparison between NADL and hog cholera virus (19) . The significance of these insertions is not known at this time, but it is tempting to speculate on the role of these sequences in the cytopathic NADL and Osloss strains of BVDV. Clearly, sequence information is needed on non-cytopathic strains of BVDV.
As mentioned previously, the order of the BVDV proteins on the genome was determined using antisera made to defined virus-encoded peptides (5) . The genome order beginning at the 5' end is p20-gp48-gp25-gp53-p30?-pl25(p54-p80)-p38?-p58-p75. The p30 and p38 proteins have not been directly identified at this time. The genetic structure of BVDV shares many common features with the members of the Flaviviridae family (3) such as a positive-stranded genomic RNA, a genome lacking a 3' poly (A) tract and a genome with a single large ORF which generates precursor polypeptides that are proteolytically processed to form the mature viral proteins. The coding strategy of BVDV is highly suggestive of p20 functioning as a nucleoprotein and the three glycoproteins, gp48, gp25 and gp53, as virion structural proteins (4) . A sequence comparison between BVDV and various flaviviruses did not show any extended regions of homology (3). However, the genomic organisation and hydropathic profiles of the amino acid sequences has led to the suggestion that the pestiviruses be included in the family Flaviviridae (3, 4) . This suggestion has not met with universal acceptance (19) , but it does permit those who work with pestiviruses to frame future experiments in the context of literature on flaviviruses. Resumen: Nuestra comprensión de la biología molecular del virus de la diarrea viral bovina (virus BVD) ha conocido grandes progresos en los últimos años. Gracias al desarrollo de los anticuerpos monoclonales (ACM), se pudo identificar , un antígeno clave del virus BVD y, al mismo tiempo, aportar la prueba de que existen variaciones considerables en esta proteína. Los ACM, en particular aquellos dirigidos contra la proteína p80, se pueden desarrollar para ser usados en las pruebas diagnósticas; otros pueden ser útiles para los estudios epidemiológicos del virus BVD a nivel molecular. El éxito de la clonación del virus B VD y del virus de la peste porcina clásica permitirá crear sondas de ácidos nucleicos que se podrán usar en las pruebas diagnósticas de rutina, en los estudios sobre la patogenia y para detectar la contaminación de sustancias biológicas por el virus BVD. La identificación de antígenos clave del virus BVD y su clonación molecular abren perspectivas promisorias: la obtención de vacunas con otro virus como vector, que tendrán a la vez la eficacia de las vacunas con virus vivo modificado y la inocuidad de las vacunas inactivadas. Queda, sin embargo, mucho por hacer para establecer la significación de la variación antigénica del virus BVD vinculada con la protección del feto en desarrollo.
